Catalog No.
PHB27501
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human CTAG2 (Leu87-Asp141).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Cancer/testis antigen 2, CT2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, CT6.2, L antigen family member 1, LAGE-1, CTAG2, ESO2, LAGE1
Purification
Purified by antigen affinity column.
Accession
O75638
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer., PMID:38309723
Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1., PMID:33237767
Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation., PMID:29473162
Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection., PMID:28800944
The Prevalence of Cancer-Associated Autoantibodies in Patients with Gastric Cancer and Progressive Grades of Premalignant Lesions., PMID:28768706
Autoantibody biomarkers for the detection of serous ovarian cancer., PMID:28427776
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade., PMID:27294163
Plasma Autoantibodies Associated with Basal-like Breast Cancers., PMID:26070530
Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens., PMID:24604332
Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma., PMID:24457462
MAGE-A3 is highly expressed in a subset of colorectal cancer patients., PMID:23390371
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors., PMID:23263452
Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy., PMID:21247062
Yeast-based identification of prostate tumor antigens provides an effective vaccine platform., PMID:20393012
Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays., PMID:19041653
Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue., PMID:15756003
[Expression of NY-ESO-1/LAGE-1 genes in hepatocellular carcinoma and autologous humoral responses induced thereby]., PMID:15730810
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1., PMID:15623618
Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer., PMID:15516106
Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display., PMID:14747957
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy., PMID:14738769
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer., PMID:14680360
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer., PMID:14522938
Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients., PMID:12932233
A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved., PMID:12384295
LAGE-1, a new gene with tumor specificity., PMID:9626360
For research use only. Not for human or drug use.
